Navigation Links
Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors
Date:10/25/2007

SAN DIEGO, Oct. 25 /PRNewswire/ -- Novocell, Inc., a leading stem cell engineering company, today announced the appointment of Orville G. Kolterman, M.D., Senior Vice President, Clinical & Regulatory Affairs of Amylin Pharmaceuticals, to the company's Board of Directors.

Dr. Kolterman joined Amylin in 1992 and has served as Senior Vice President, Clinical Affairs since February 1997 until present and as Senior Vice President, Regulatory Affairs since August 2005. At Amylin, Dr. Kolterman has been instrumental in the development of the company's first-in-class diabetes medicines, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection.

"Dr. Kolterman's breadth of experience, including the clinical development of successful diabetes therapeutics, will be invaluable to Novocell as we advance the development of our diabetes cell therapy and additional cell therapies," said Alan J. Lewis, President, Chief Executive Officer and Director of Novocell.

"I am pleased to join the Novocell board and look forward to working with the Company to help advance it's innovative platform technologies, including its human embryonic stem cell engineering, cell encapsulation and drug discovery efforts, which hold promise for the treatment of a range of chronic diseases," said Dr. Kolterman.

Prior to Amylin, Dr. Kolterman was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California, San Diego (UCSD) Medical Center. He has also served as Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver and was a member of the Diabetes Control and Complications Trial Study Group. Dr. Kolterman currently serves as a member of the Epidemiology of Diabetes Intervention and Complications Study. He is also a past-president of the California Affiliate of the American Diabetes Association. Dr. Kolterman received his M.D. from Stanford University School of Medicine.

About Novocell

Novocell is a stem cell engineering company with research operations in San Diego, CA, and Athens, GA, dedicated to creating, delivering, and commercializing cell and drug therapies to treat diseases including diabetes. Novocell is the first company to efficiently engineer human embryonic stem cells into definitive endoderm, the gatekeeper cells that differentiate into many other cells, tissues and organs. Novocell is focused on the development of a variety of technology platforms including stem cell engineering, cell encapsulation, and drug discovery. The company was founded in 1999 and merged with CyThera, Inc. and BresaGen, Inc. in 2004. For more information, visit http://www.novocell.com.

Media Contact:

Julie Rathbun

Rathbun Communications, Inc.

julie@rathbuncomm.com

(206) 769-9219


'/>"/>
SOURCE Novocell, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... LOUISVILLE, Ky. , Feb. 10, 2016 ... company utilizing its proprietary NeXosome® technology for early ... presentation of its most recent study by Dr. ... Hospital at the Society for Maternal Fetal Medicine,s (SMFM) ... , GA, February 1-6 th , 2016.  The presentation ...
(Date:2/10/2016)... York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has ... develop new vaccines and immunotherapies for infectious diseases and cancer. , ...
(Date:2/10/2016)...  Allergan plc (NYSE: AGN ) a leading ... , Allergan,s CEO and President, will be featured as ... the RBC Capital Markets Healthcare Conference on Tuesday, February ... York Palace Hotel in New York, NY ... can be accessed on Allergan,s Investor Relations web site ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... states, announced today the promotion of two long-standing principal investigators (PI) to the ... Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research PI ...
Breaking Biology Technology:
(Date:1/25/2016)... --  Unisys Corporation (NYSE: UIS ) today announced the ... Airport, New York City , to help ... enter the United States using passports that ... testing of the system at Dulles last year. The system ... January 2016. --> pilot testing of the system ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ... Market in Retail Sector 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ...
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):